Pfizers Prevnar, Abrysvo and Comirnaty suffer Q3 sales declines amid tough US market for vaccines
5.8
来源：
FiercePharma
发布时间：
2025-11-04 14:15
摘要：
Pfizer's vaccine sales have faced declines in the U.S. market during Q3, with notable drops in Comirnaty and Abrysvo, while international sales have increased. The company is also actively pursuing an acquisition of Metsera, facing competition from Novo Nordisk, which has raised its bid. This highlights Pfizer's strategic focus on expanding its portfolio and addressing market challenges.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
0.5
business_impact
1.0
scientific_rigor
0.0
timeliness_innovation
1.0
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.3
technical_barrier_competition
0.5
关键证据
Pfizer's Prevnar family of vaccines and Abrysvo suffered sales declines in the U.S.
Pfizer is involved in a bidding war for Metsera, raising its offer amid competition.
CEO indicated a focus on international markets for vaccine sales.
真实性检查
否
AI评分总结
Pfizer's vaccine sales have faced declines in the U.S. market during Q3, with notable drops in Comirnaty and Abrysvo, while international sales have increased. The company is also actively pursuing an acquisition of Metsera, facing competition from Novo Nordisk, which has raised its bid. This highlights Pfizer's strategic focus on expanding its portfolio and addressing market challenges.